• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估低体重患者预防性皮下使用未分级肝素的出血风险。

Assessment of bleeding risk in low-weight patients receiving prophylactic subcutaneous unfractionated heparin.

机构信息

Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.

Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.

出版信息

Vasc Med. 2023 Oct;28(5):443-448. doi: 10.1177/1358863X231189758. Epub 2023 Aug 9.

DOI:10.1177/1358863X231189758
PMID:37555546
Abstract

BACKGROUND

Underweight patients may be at an increased risk of bleeding while receiving venous thromboembolism (VTE) prophylaxis. Additional evidence is needed to identify patient-specific factors associated with bleeding. The objective of the study was to describe the incidence and identify risk factors associated with bleeding in low-weight (⩽ 60 kg) adult patients receiving subcutaneous unfractionated heparin (SQH) for VTE prophylaxis.

METHODS

This was a single-center, retrospective, nested case-control study of low-weight patients receiving SQH for VTE prophylaxis for ⩾ 48 hours. Cases, patients with clinically relevant bleeding while receiving SQH, and controls, patients without a bleeding event, were matched in a 1:3 ratio for age, sex, primary service (surgical or medical), and time at risk of bleeding on SQH to determine factors associated with bleeding.

RESULTS

A total of 3761 patients met the inclusion criteria, of which 38 cases of clinically relevant bleeding were identified. The bleeding incidence was 1% at hospital day 6 and 2.8% at hospital day 14. Most patients in this study (69%) received SQH 5000 units three times daily. ICU admission at SQH start was associated with bleeding, OR 2.97 (95% CI 1.21-7.29).

CONCLUSION

Bleeding in low-weight patients on prophylactic SQH was uncommon. Patients admitted to the ICU at time of SQH start may be at a higher risk of bleeding. Further studies are needed to detect additional risk factors associated with bleeding and investigate the effects of reduced dosing in this population.

摘要

背景

接受静脉血栓栓塞症(VTE)预防治疗的体重不足患者可能有更高的出血风险。需要更多的证据来确定与出血相关的患者特定因素。本研究的目的是描述低体重(≤60kg)成年患者接受皮下普通肝素(SQH)预防 VTE 治疗时出血的发生率,并确定与出血相关的危险因素。

方法

这是一项单中心、回顾性、嵌套病例对照研究,纳入了接受 SQH 预防 VTE 治疗≥48 小时的低体重患者。病例组为接受 SQH 治疗时发生临床相关出血的患者,对照组为无出血事件的患者,按照年龄、性别、主要科室(外科或内科)和 SQH 出血风险时间进行 1:3 匹配,以确定与出血相关的因素。

结果

共有 3761 名患者符合纳入标准,其中 38 例发生临床相关出血。出血发生率在住院第 6 天为 1%,在住院第 14 天为 2.8%。本研究中大多数患者(69%)接受每日三次 5000 单位 SQH。SQH 开始时入住 ICU 与出血相关,OR 2.97(95%CI 1.21-7.29)。

结论

接受预防性 SQH 治疗的低体重患者出血并不常见。在 SQH 开始时入住 ICU 的患者可能有更高的出血风险。需要进一步研究以发现与出血相关的其他危险因素,并研究该人群中减少剂量的效果。

相似文献

1
Assessment of bleeding risk in low-weight patients receiving prophylactic subcutaneous unfractionated heparin.评估低体重患者预防性皮下使用未分级肝素的出血风险。
Vasc Med. 2023 Oct;28(5):443-448. doi: 10.1177/1358863X231189758. Epub 2023 Aug 9.
2
Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition.对于外科重症监护病房(Surgical ICU)患者,标准的皮下给予未分级肝素(unfractionated heparin)进行静脉血栓栓塞(venous thromboembolism)预防,会导致因子 Xa 抑制作用低于治疗水平。
Intensive Care Med. 2012 Apr;38(4):642-8. doi: 10.1007/s00134-011-2453-4. Epub 2012 Jan 10.
3
Subcutaneous heparin for prophylaxis of venous thromboembolism in deep brain stimulation surgery: evidence from a decision analysis.皮下注射肝素预防深部脑刺激手术中静脉血栓栓塞:一项决策分析的证据
Neurosurgery. 2009 Aug;65(2):276-80; discussion 280. doi: 10.1227/01.NEU.0000348297.92052.E0.
4
Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.评价普通肝素、低分子肝素和磺达肝癸钠用于癌症重症患者的药物性静脉血栓栓塞预防。
J Thromb Haemost. 2018 Dec;16(12):2492-2500. doi: 10.1111/jth.14317. Epub 2018 Nov 15.
5
Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.成年癌症患者群体中静脉血栓栓塞预防措施的回顾性评估。
J Oncol Pharm Pract. 2010 Mar;16(1):27-31. doi: 10.1177/1078155209104379. Epub 2009 Apr 28.
6
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.接受化疗的门诊癌症患者静脉血栓栓塞的一级预防
Cochrane Database Syst Rev. 2014 Aug 29(8):CD008500. doi: 10.1002/14651858.CD008500.pub3.
7
Clinical Experience With Pharmacological Venous Thromboembolism Prophylaxis in the Underweight and Critically Ill.体重过轻和危重症患者药物性静脉血栓栓塞预防的临床经验
Ann Pharmacother. 2016 Oct;50(10):832-9. doi: 10.1177/1060028016657347. Epub 2016 Jul 1.
8
Incidence of Venous Thromboembolism and Safety of Perioperative Subcutaneous Heparin During Inflatable Penile Prosthesis Surgery.充气阴茎假体手术中皮下肝素围术期应用的静脉血栓栓塞发生率和安全性。
Urology. 2021 Nov;157:155-160. doi: 10.1016/j.urology.2021.08.002. Epub 2021 Aug 16.
9
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.随机对照试验比较高剂量与低剂量低分子肝素在需要侵入性机械通气的严重 COVID-19 肺炎和凝血病住院患者中的疗效和安全性 (COVID-19 HD):研究方案的结构化总结。
Trials. 2020 Jun 26;21(1):574. doi: 10.1186/s13063-020-04475-z.
10
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.皮下注射普通肝素用于静脉血栓栓塞症的初始治疗。
Cochrane Database Syst Rev. 2017 Feb 14;2(2):CD006771. doi: 10.1002/14651858.CD006771.pub3.

引用本文的文献

1
Systematic review of venous thromboembolism (VTE) occurrence in hospitalized patients receiving prophylactic unfractionated heparin twice vs. three times daily.对接受每日两次与每日三次普通肝素预防性治疗的住院患者静脉血栓栓塞(VTE)发生率的系统评价。
J Thromb Thrombolysis. 2025 Jun 26. doi: 10.1007/s11239-025-03137-8.
2
Development and validation of a novel bleeding risk prediction tool for aspirin users with a low body mass index.一种针对低体重指数阿司匹林使用者的新型出血风险预测工具的开发与验证
Sci Rep. 2025 Feb 7;15(1):4624. doi: 10.1038/s41598-025-88327-3.